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7RESEARCH ARTICLE Open AccessVitamin B6 reduces hippocampal apoptosis in
experimental pneumococcal meningitis
Denise C Zysset-Burri1,2,3, Caroline L Bellac4, Stephen L Leib1,4* and Matthias Wittwer1Abstract
Background: Bacterial meningitis caused by Streptococcus pneumoniae leads to death in up to 30% of patients and
leaves up to half of the survivors with neurological sequelae. The inflammatory host reaction initiates the induction
of the kynurenine pathway and contributes to hippocampal apoptosis, a form of brain damage that is associated
with learning and memory deficits in experimental paradigms. Vitamin B6 is an enzymatic cofactor in the
kynurenine pathway and may thus limit the accumulation of neurotoxic metabolites and preserve the cellular
energy status.
The aim of this study in a pneumococcal meningitis model was to investigate the effect of vitamin B6 on
hippocampal apoptosis by histomorphology, by transcriptomics and by measurement of cellular nicotine amide
adenine dinucleotide content.
Methods and results: Eleven day old Wistar rats were infected with 1x106 cfu/ml of S. pneumoniae and
randomized for treatment with vitamin B6 or saline as controls. Vitamin B6 led to a significant (p > 0.02) reduction
of hippocampal apoptosis. According to functional annotation based clustering, vitamin B6 led to down-regulation
of genes involved in processes of inflammatory response, while genes encoding for processes related to circadian
rhythm, neuronal signaling and apoptotic cell death were mostly up-regulated.
Conclusions: Our results provide evidence that attenuation of apoptosis by vitamin B6 is multi-factorial including
down-modulation of inflammation, up-regulation of the neuroprotective brain-derived neurotrophic factor and
prevention of the exhaustion of cellular energy stores. The neuroprotective effect identifies vitamin B6 as a potential
target for the development of strategies to attenuate brain injury in bacterial meningitis.
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Bacterial meningitis (BM) caused by S. pneumoniae is a
life-threatening disease associated with high mortality
and morbidity rates. In spite of effective antimicrobial
therapy and intensive care, about 50% of survivors suffer
from long-term sequelae, including hearing loss, neuro-
functional problems, seizure disorders, sensory-motor
deficits, and persisting learning and memory difficulties
[1-3].
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distribution, and reproduction in any mediumhave been demonstrated in patients [4] and in corre-
sponding experimental animal models of BM. Damage
to the hippocampal formation has been associated with
learning and memory impairments [3,5].
Inflammatory conditions in the brain induce trypto-
phan (TRP) degradation through the kynurenine (KYN)
pathway, resulting in several neuroactive metabolites
which can be both, neurotoxic or neuroprotective
(Figure 1). The KYN pathway may be involved in the
mechanisms leading to brain damage associated with in-
flammatory brain diseases, such as multiple sclerosis or
cerebral malaria [6,7]. The pathophysiology of pneumo-
coccal meningitis is initiated by activation of the im-
mune system of the host, leading to the induction of
metabolic pathways in the brain [6]. Increased TRP deg-
radation caused by the activation of the KYN pathway
may also be involved in the processes that result inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Schematic of the kynurenine pathway in the rat brain. Tryptophan is metabolized over multiple steps into quinolinic acid, finally
resulting in de novo synthesis of NAD+. Several neuroactive intermediates are included in this pathway: neuroprotective kynurenic acid,
neurotoxic 3-hydroxykynurenine and neurotoxic 3-hydroxyanthranilic acid. Neurotoxic intermediates are written in red, neuroprotective ones in
green [6,7].
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[2,6,8]. The neurotoxic effect of the intermediates
3-hydroxykynurenine and 3-hydroxyanthanilic acid in-
volves the generation of superoxide and hydrogen pe-
roxide that contribute to oxidative processes implicated
in the pathophysiology of meningitis. In contrast, neu-
roprotective kynurenic acid (KYNA), an antagonist of
the excitotoxic N-methyl-D-aspartate (NMDA) receptor,
protects from excitotoxic brain damage in experimental
BM [6]. Furthermore, the catabolism of TRP over the
KYN pathway is the exclusive de novo synthesis pathway
for nicotine amide adenine dinucleotide (NAD+) in
eukaryotic cells [6]. NAD+ fuels the poly(adenosine
5′-diphosphate (ADP)-ribose) polymerase whose over-
activation during neuro-inflammatory diseases may de-
plete intracellular NAD+ levels and thus, resulting in
necrotic cell death [9]. Therefore, the KYN pathway in-
duced in pneumococcal meningitis may influence the
fate of neuronal tissue over NAD+ supply [6,9].
Pyridoxal 5′-phosphate, the active form of vitamin B6,
optimizes the substrate flux in the KYN pathway by act-
ing as cofactor for two key enzymes, KYN aminotrans-
ferase and kynureninase [10]. Administration of vitamin
B6 may attenuate neuronal cell death in BM by pre-
venting both, the accumulation of neurotoxic intermedi-
ates of the KYN pathway and cellular energy depletion
by enhancing the de novo synthesis of NAD+.
In the present study, we evaluated the mode of action
of vitamin B6 by microarrays. We interpreted the
transcriptomic data using biological system based ana-
lysis rather than a “gene by gene” approach. The Gene
Ontology (GO) [11] and the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway [12] databaseprovide a basis for grouping genes according to their
molecular functions, biologic processes and cellular com-
ponents, and their involvement in concordant cellular
pathways, respectively.
Histopathological analysis showed that vitamin B6 sig-
nificantly reduced hippocampal apoptosis in pneumo-
coccal meningitis. Furthermore, based on fluorescence
measurements of hippocampal NAD+ levels, an effect
of vitamin B6 in preserving cellular energy stores was
found.
Methods
Ethics statement
All animal studies were approved by the Animal Care
and Experimentation Committee of the Canton of Bern,
Switzerland (Nr. 26/07), and followed the Swiss national
guidelines for the performance of animal experiments.
Model of experimental pneumococcal meningitis
We used an established model of experimental pneumo-
coccal meningitis in infant rats [13]. On postnatal day
11, Wistar rats (n = 28) were infected by intracisternal
injection of 10μl of saline solution containing 1 × 106
cfu/ml of S. pneumoniae (serotype 3). At time of in-
fection, animals (n = 14) received 360μl of vitamin
B6 subcutaneously (s.c.; 600mg/kg; Streuli, Uznach,
Switzerland). Placebo-treated animals (n = 14) were
injected s.c. with 360 μl of 0.85% NaCl. Eighteen
hours after infection, all animals were treated s.c. with
100 mg/kg of the antibiotic ceftriaxone (Roche Pharma,
Reinach, Switzerland) and a second dose of vitamin B6
or 0.85% NaCl was administered. At the same time
point, infection was documented by quantitative culture
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weighed and clinically assessed using the following score
system: 1 for comatose animals, 2 for rats that do not
turn upright after positioning on the back, 3 for animals
that turn within 30 s, 4 for animals that turn within less
than 5 s and 5 for rats with normal activity [13]. Twenty
four hours after infection, the rats were sacrificed by an
overdose of intraperitoneal (i.p.) pentobarbital (100 mg/kg,
Esconarkon, Streuli & Co. AG, Uznach, Switzerland).
For NAD+ measurements, Wistar rats (n = 15) were
infected by intracisternal injection of 10 μl of 1×106 cfu/ml
of S. pneumoniae. At time of infection, animals were ran-
domized for treatment with vitamin B6 (600 mg/kg s.c. 0
and 18 h p.i., n = 6) or an equal volume (360 μl) of 0.85%
NaCl (s.c., n = 9). Three saline-treated rats were sacrificed
at the same time point (0h p.i.). The antibiotic therapy
was started 18 h post-infection (100 mg/kg ceftriaxone,
s.c.). At the same time point, 3 vitamin B6- and 3 saline-
treated rats were sacrificed (18 h p.i.), and a second appli-
cation of vitamin B6 and 0.85% NaCl, respectively, were
administered to the remaining 6 animals. These animals
were sacrificed 24 h after infection (24 h p.i.).
Tissue processing
Immediately after sacrifice, the animals were perfused
via the left cardiac ventricle with 30 ml of RNAse-free
ice-cold phosphate buffered saline (PBS). The brains
were dissected followed by removal of the meninges and
segmentation of the brains into the 2 hemispheres. The
right hemisphere was fixed in 4% paraformaldehyde
(Grogg, Stettlen-Deisswil, Switzerland) in PBS for 3 days
at 4°C and then cryo-protected in 18% sucrose at 4°C
until further processing for histopathological assessment
of brain injury. From the left hemisphere the hippocam-
pus was dissected in ice-cold PBS, stored in RNAlater®
(Ambion Europe Ltd., Huntingdon, UK) for 1 day at 4°C
and subsequently at −80°C until isolation of RNA. For
NAD+ measurements, the hippocampus of the left
hemisphere was frozen on dry ice and stored at −80°C.
Histopathology
To assess the brain damage caused by BM the brains
were analyzed histomorphologically. The cryo-protected
brains were frozen in 2-methylbutane (−50°C), and from
each animal four 45 μm cryo-sections of the dentate
gyrus were cut using a Cryostat (Leica CM1850 cryostat)
and transferred onto a gelatin/chrom alum-coated glass
slide. The slides were put in Xylol, hydrated, Nissl
stained with cresyl violet, dehydrated and mounted with
Entellan® (Merck, Darmstadt, Germany). The amount of
apoptotic cells in the dentate gyrus of the hippocampus
and of the extent of damage to the cerebral cortex were
evaluated using bright-field microscopy. Neurons of the
dentate granule cell layer with morphological changescharacteristic for apoptosis (condensed, fragmented nu-
clei and/or apoptotic bodies) were counted in 3 visual
fields (400× magnification) in each of the 2 blades of the
dentate gyrus. An average score per animal was calcu-
lated from all sections evaluated, applying the following
scoring system: 0–5 cells = 0, 6–20 cells = 1 and >20
cells = 2 [14]. The cortical damage was assessed as the
amount of damage of the total volume of the cortex as
previously reported [15].
RNA isolation, quality control and chip hybridization
From tissue samples of the hippocampus total RNA was
isolated using the magnetic beads based EZ1 RNA Uni-
versal Tissue Kit (Qiagen, Basel, Switzerland) and EZ1
BioRobot (Qiagen). Tissue stabilized in RNAlater® was
mixed with 750 μl QIAzol® Lysis reagent. Samples were
immediately homogenized by a rotor-stator homogenizer
(TissueRuptor®, Qiagen). After incubation for 5 min at
room temperature, 150 μl chloroform (Grogg) was added
to the homogenized tissue samples. A centrifuging step
for 15 min at 4°C and 12’000 rpm resulted in the separ-
ation of the sample into 3 phases. 300 μl of the upper
phase containing RNA was used as starting material for
RNA isolation using the EZ1 BioRobot, following the
manufacturer’s protocol.
Quantification of RNA was performed on the Agilent
2100 Bioanalyzer platform (RNA 6000 Nano, Agilent
Technologies, Waldbronn, Germany) and validated on
the NanoDrop® (NanoDrop, Wilmington, USA) device.
From 28 histopathologically evaluated rat brains with
evidence for apoptosis, RNA extracts from 5 vitamin B6-
and 5 saline-treated animals were selected randomly for
array hybridization. Chip hybridization was performed in
cooperation with the Lausanne DNA Array Facility
(University of Lausanne, Switzerland). Double-stranded
cDNAs were synthesized from 100ng of total RNA using
T7 promoter-(N) 6 primers (Affymetrix, Santa Clara,
CA) and the Whole Target Transcript cDNA synthesis
kit (Affymetrix). Quantification and quality control of
cDNA was performed by NanoDrop® and Agilent 2100
Bioanalyzer platform, respectively. Three microgram of
fragmented, biotinylated cDNA was hybridized in a
Hybe Oven (GeneChip® 640) overnight onto com-
mercially available GeneChip® Rat Gene 1.0 ST Array
(Affymetrix) containing over 27’000 rat genes. The hy-
bridized samples were stained with streptavidin phyco-
erythrin and the signal was amplified by a biotinylated
anti-streptavidin antibody. Washing, staining and ampli-
fication were performed in an Affymetrix GeneChip®
Fluidics Station 450. The components required for these
steps were provided by the GeneChip® Hybridization,
Wash, and Stain kit (Affymetrix). Microarrays were
scanned in an Affymetrix GeneArray® scanner 3000.
Resulting image files served as basis for the calculation
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Operating Software (GCOS).Datamining
All data is MIAME compliant and has been deposited in
the ArrayExpress database of the European Bioinformat-
ics Institute (http://www.ebi.ac.uk/arrayexpress, acces-
sion number E-MEXP-3555).
Chip data analysis was carried out on the R platform
for statistical programming using packages from the
Bioconductor project [16]. Because of the asymmetric
distribution of microarray data, expression values were
log2 transformed. Background correction, quantile nor-
malization and probe set summary (robust regression,
only perfect matches) were performed with non linear
methods based on the robust multi average (RMA) func-
tion of the Bioconductor affy package [17]. Chip quality
control was explorative evaluated using box plots of the
raw log scale intensities and MA-plots visualizing signal
intensity dependent effects on the log-ratios (affy
package).
To reduce the number of hypothesis to be tested in
the adjacent significance tests, genes were filtered based
on the following criteria: all genes that were expressed
under the estimated background intensity of 26 fluores-
cent units on at least 4 of the 10 arrays and genes with
an interquantile range of less than 0.001 were excluded.
Differentially expressed genes were identified by using
the linear models for microarray data (limma) package
[18] which implements a moderated t-statistic for signifi-
cance testing. The type 1 error rate was adjusted to 1%
using the Benjamini-Hochberg false discovery rate algo-
rithm [19]. Genes which had cross-hybridized on the
chip or which had no annotation in any existing data
bank were excluded from further analysis.
The transcriptomic data were evaluated by the func-
tional annotation clustering tool of DAVID (Database
for Annotation, Visualization and Integrated Discovery)
bioinformatics (http://david.abcc.ncifcrf.gov/) for GO
statistics [11] and by biological system based analysis
using the KEGG pathway database (http://www.genome.
jp/kegg) for pathway analysis [12].Table 1 TaqMan® gene expression assays (Applied Biosystem
Name
Brain-derived neurotrophic factor (BDNF)
Neuronal PAS domain protein 4 (Npas4)
Lysozyme 2 (Lyz2)
Platelet-activating factor acetylhydrolase 2 (Pafah2)
Nuclear receptor subfamily 4, group A, member 1 (Nr4a1)
Ribosomal protein L24 (Rpl24)
The genes selected for chip validation by real time PCR and their corresponding ref
Rpl24 was used as housekeeping gene.Chip validation by real time PCR
cDNA was synthesized from 1.5 μg of total RNA using
the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA), according to the
manufacturer’s protocol. The cDNA samples were di-
luted 1:5 with RNAse-free water and aliquots were
stored at −20°C. Real time PCR was performed using the
QuantiFast Probe PCR kit from Qiagen (composed of
Hot Star Taq Plus DNA polymerase and dNTP mix
in PCR buffer) and TaqMan® Gene Expression Assays
(Applied Biosystems).
All reactions were carried out as duplicates. Template
cDNA was amplified with the Rotor-Gene Q platform
(Corbet RESEARCH) operating with the Run on Soft-
ware version “Rotor-Gene 1.7.87”.
The primers used for this PCR and their reference se-
quences (RefSeq) as well as their ordering numbers of
Applied Biosystems are listened in Table 1. The delta Ct
values were calculated based on normalization to the
housekeeping gene ribosomal protein L24 (Rpl24).
Hippocampal NAD+ levels
For assessment of cellular energy status NAD+ levels
were measured in hippocampal tissue from rats with BM
treated with vitamin B6 or saline at 0, 18 and 24 hours
after infection (n=3 for each experimental group and
time).
Frozen dissected hippocampi were homogenized 1:10
(wt/vol) in ice-cold assay buffer (50 mM Tris and 2 mM
MgCl2, pH 8.0) and 50 μl of the homogenates were
transferred into a 96-well fluorescence plate. NAD+
was quantified according to the method of Putt and
Hegenrother [20]. The plate was read on a SpectraMax
Plus (Molecular Devices, Sunnyvale, CA) with an excita-
tion of 360 nm and an emission of 445 nm, and values
were plotted against a NAD+ calibration curve (Sigma,
St. Louis, MO).
Results
Clinical parameters of meningitis
By 18 h after infection, all rats infected with S. pneu-
moniae had meningitis, as evidenced by positive bac-
terial titers in the CSF (log10 6.8 - log10 8.0 cfu/ml)s)
RefSeq Assay number
NM_012513.3 Rn01484924_m1
NM_153626.1 Rn00596522_m1
NM_012771.2 Rn00562794_m1
NM_177932.2 Rn00710058_m1
NM_024388.1 Rn01533237_m1
NM_001007637.1 Rn01455518_g1
erence sequences (RefSeq) and ordering numbers of Applied Biosystems.
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infection, the animals treated with vitamin B6 lost 0.50 ±
0.04 g of body weight, whereas the weight of placebo-
treated animals was reduced by 0.74 ± 0.02 g (p < 0.07,
unpaired t test).
Apoptotic cells in the dentate gyrus
Infection with S. pneumoniae caused apoptosis in the
subgranular zone of the dentate gyrus as reported pre-
viously (Figure 2A) [21]. At 24 h post-infection rep-
resenting the acute phase of the disease, the mean score
of apoptotic neurons was 1.6 ± 0.1 in saline-treated ani-
mals. In animals treated with vitamin B6 the apoptotic
damage score was significantly lower (p < 0.02, unpaired
t test) with a mean score of apoptotic cells of 1.2 ± 0.1
(Figure 2B). In contrast, vitamin B6 treatment had no
significant effect on cortical damage (data not shown).
Microarrays
An overview of the workflow of microarray analysis
chosen for this work is represented in Figure 3.
From over 27’000 rat genes represented on the chip,
17’957 genes were expressed over background level in
the hippocampus of rat brains. After significance testing,
the expression of 120 annotated genes was found to be
influenced by vitamin B6 treatment (see Additional file 1:
Table S1).
Cluster analysis
Functional annotation clustering of significantly regu-
lated genes by DAVID bioinformatics resulted in clusters
of genes with possible roles in the mode of action of
vitamin B6. The corresponding GO terms found to be
overrepresented in our gene list belong to processes ofsaline
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Figure 2 Apoptosis in the rat hippocampal dentate gyrus after infect
neurons forming apoptotic bodies (arrowhead), a morphological feature ch
lower and upper blade of the hippocampal dentate gyrus (Cresyl violet, origin
cells (represented by the horizontal lines) in the vitamin B6-treated group is s
t test, p > 0.02). C: Hippocampal NAD+ levels were measured at 3 different tim
rats (solid circles; vertical bars show standard deviation) gradually decreases o
hippocampus of infected rats. In contrast, the NAD+ level of rats treated with
post-infection. Statistical analysis was performed using GraphPad Prism 4 (Grathe inflammatory response, circadian rhythm, neuronal
signaling and apoptotic cell death (Figure 4A – D).
Upon vitamin B6 treatment many genes involved in
processes of the inflammatory response (Figure 4A) were
down-regulated such as pro-inflammatory cytokines and
chemokines. In contrast, the majority of genes involved
in processes of the circadian rhythm (Figure 4B) as well
as of neuronal signaling (Figure 4C) and apoptosis
(Figure 4D) were up-regulated.
A valuable tool to assign a set of genes to cellular
pathways is the KEGG pathway database. The pathways
over-represented in our set of genes were associated to
the highly conserved mitogen-activated protein kinase
(MAPK) cascade (see Additional file 2: Figure S1) as
well as to the circadian rhythm (see Additional file 3:
Figure S2). The MAPK pathway is involved in various
cellular functions including inflammatory processes (e.g.
down-stream signaling of IL-1) and neuronal signaling
(e.g. via brain-derived neurotrophic factor), both processes
also found by DAVID bioinformatics.Real time PCR
To validate the microarray data by an independent sec-
ond method the expression levels of 5 genes (Table 1)
were assessed by real time PCR. These genes were se-
lected due to their putative importance in the mode of
action of vitamin B6 in reducing hippocampal apoptosis,
i.e. deriving from the apoptosis/cell death cluster, and
because their expression levels span a wide signal range
of the microarray.
The Pearson correlation between real time PCR and
microarray data was r = 0.962 with a significant p value
of 0.009.vitamin B6 0h 18h 24h
0
1
2
3
4
N
A
D
+ [
M
]
C
ion with S. pneumoniae. A: Histomorphological analysis show
aracterisitc for programmed cell death and evenly distributed over the
al magnification 20× and 40× (insert)). B: The mean score of apoptotic
ignificantly smaller than the score of placebo-treated rats (unpaired
e points after infection. The amount of NAD+ in placebo-treated
ver time as an index of depletion of cellular energy stores in the
vitamin B6 (bare circles) rises from the time of infection to 24 h
phPad Software, San Diego California, USA).
GeneChip® Rat Gene 1.0 ST Array 
(Affymetrix) containing over 27`000 genes  
(rat genome) 
Subtraction of all genes expressed 
below background and with a small 
signal variance 
Number of expressed genes in the rat 
brain: 17`957 
Significance testing / type I error 
correction using limma package 
Number of differentially expressed genes 
between vitamin B6- and placebo-treated 
rats: 120 
Datamining 
Analysis tools and chip 
validation 
Cluster analysis  
KEGG: pathway analysis DAVID bioinformatics 
Apoptosis/cell 
death cluster Circadian rhythm cluster 
Chip validation based on 
RNA level Apoptosis parameters 
PCR 
Inflammatory 
response cluster Neuronal signaling cluster 
Correlation between array 
and apoptosis score 
Figure 3 Data analysis flowchart. Overview of the workflow of data analysis chosen for the present work. Analysis was carried out on
the R platform for statistical programming, cluster analysis was performed according to DAVID bioinformatics and pathway analysis was
based on KEGG.
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score
Pearson correlation between RNA expression levels of
selected genes and apoptosis score was highly significant
with p values between < 0.001 and 0.005 (Figure 5). The
transcripts chosen for the correlation analysis were the
same as assessed by real time PCR.
Due to these highly significant correlations between
expression level and apoptosis score, the selected genes
are candidates for apoptosis markers, although the time
point is late (24 h post-infection) in regard to the notion
that pro- and anti-apoptotic factors change at 12-16 h
after infection [22]. However, further experiments are
needed to determine the application of these genes as
potential apoptosis markers.NAD+ levels in hippocampal tissue
Hippocampal NAD+ levels of rats with BM dropped
after infection, indicating a decrease of cellular energy in
the course of the disease. In contrast to the placebo
group, the amount of NAD+ in the hippocampus of rats
treated with vitamin B6 increased during the same time
period (Figure 2C). Thus, an effect of vitamin B6 to pre-
serve cellular energy stores, likely by optimizing the sub-
strate flux in the kynurenine pathway, was found during
the acute phase of BM when hippocampal apoptosis
develops.
Discussion
Apoptosis of cells in the hippocampal dentate gyrus is a
characteristic form of brain damage in BM [3,21]. In
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Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Functional annotation cluster. The 120 significantly expressed genes were clustered into functionally related groups such as
inflammatory response (A), circadian rhythm (B), neuronal signaling (C) and apoptosis / cell death (D) based on DAVID bioinformatics. The genes
belonging to the individual clusters are listened on the right side. The suitable functions with the corresponding GO terms are mentioned below
the clusters. Green marked squares state that the gene is up-regulated in that GO term, red marked squares stand for down-regulated genes, and
grey filled squares mean that the gene is not involved in that process.
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tate gyrus with learning and memory deficits has been
shown [5]. The present study demonstrates that treat-
ment with vitamin B6 reduces the number of apoptotic
cells in the hippocampal dentate gyrus. We investigated
the mechanisms underlying this neuroprotective effect
by studying the influence of vitamin B6 on the transcrip-
tome and on cellular energy stores.
In the model used, hippocampal apoptosis starts to
occur during the acute phase of BM (18-24 h) with a
peak in the sub-acute phase at 36 h, and reaches control
levels in the late phase of the disease (46-72 h). Recent
studies in our lab showed that in the acute phase of BM,
genes that are significantly expressed in the hippocam-
pus and cortex are mainly involved in processes of the
immune and inflammatory response [23]. The innate im-
mune system has a predominant role in immune defense
in the otherwise immune privileged brain tissue. How-
ever, neurological complications secondary to BM [3]
suggest that the host defense mechanisms are inefficient
in eliminating the pathogen and furthermore, that the
host inflammatory reactions contribute considerably to
the brain damage observed in the disease. As shown pre-
viously, the major events on transcriptional level con-
cerning the regulation of the host immune response
occur within the first 3 days after infection [23].
A promising candidate for pre-treatment of BM is vita-
min B6 administered during the acute phase of the dis-
ease. A prerequisite for the application of a therapeutic
target is the understanding of the processes leading to the
desired effects, in the case of vitamin B6 to a reduction of
hippocampal apoptosis. Thus, in the present study, we fo-
cused on the mechanisms that take place as a conse-
quence of vitamin B6 treatment in the acute phase of BM.
The time point for the second application of vitamin
B6 (18 h post-infection) and the endpoint at 24 h post-
infection were chosen during the acute phase of BM
according to recent findings which define a time window for
therapeutic interventions during this phase of the disease.
In order to handle the huge data mass resulting from a
microarray study, we clustered the significantly regulated
transcripts according to their involvement in given bio-
logical processes (Figure 4).
Inflammatory response
The first step in immune activation is the recognition of
bacterial products by pattern recognition receptors, suchas Toll-like receptors (TLRs), expressed on resident cells
of the central nervous system (CNS) [3]. Experimental
studies showed that primary mouse microglial cells, the
resident macrophages of the CNS, are activated upon
stimulation with agonists of several TLRs. Activated
microglia release inflammatory mediators such as nitric
oxide (NO) or activin A. Activin A is a member of the
transforming growth factor-β (TGF-β) family which
plays a central role in different aspects of cell growth
and differentiation [24]. Previous studies showed that
activin A is increased in the CSF of patients suffering
from BM. Furthermore, activin A may decrease the secre-
tion of NO and pro-inflammatory mediators by activated
microglia, and enhances microglial proliferation, sugges-
ting that activin A may counteract the activation of micro-
glial cells in BM [25]. The biological functions of members
of the TGF-β family are mediated by 2 types of transmem-
brane serine/threonine kinase receptors (type I and II) that
are expressed on activated microglial cells. Therefore,
microglia is not only the source but also the target cells of
activin A in the CNS [25]. The down-regulation of the
activin A receptor type II-like 1 (ID 382555, Figure 4A)
upon vitamin B6 treatment may indicate a reduced activa-
tion of microglia and thus, a decreased release of tissue-
destructive mediators.
G protein coupled receptors (GPCRs) change their
conformation upon stimulation by an activating signal.
This activated state is controlled by regulators of G pro-
tein signaling (RGS) [26,27]. RGS2 (ID 377853) as well
as GPCR3 (ID 435019) are up-regulated in vitamin B6-
treated rats compared to saline-treated animals, sug-
gesting an involvement of G protein signaling in cellular
processes leading to a reduction of hippocampal apop-
tosis (Figure 4A). Recent studies documented that
among the RGS family, RGS2 plays a prominent role in
regulating synaptic transmission and plasticity in hippo-
campal neurons [26]. It is therefore likely that increased
RGS2 levels modulate synaptic output, probably leading
to an elevated survival of neurons upon vitamin B6
treatment.
The GPCR3 endothelinB (ETB) has been found to be
important for the physiological reduction of neuronal
apoptosis in the dentate gyrus during postnatal deve-
lopment. Furthermore, ETB receptors are involved in
pathological apoptosis in the dentate gyrus, especially in
a rabbit model of pneumococcal meningitis [28]. These
data suggest a role for the ETB receptor as an anti-
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Figure 5 Pearson correlation between RNA expression level
and apoptosis score. RNA expression data of individual rats are
based on chip analysis, the apoptosis score is the mean value of
apoptotic cells of corresponding rat brains. Expression levels of up-
regulated genes such as BDNF (A) (Pearson correlation p = 0.002),
Npas4 (C) (p = 0.005) and Nr4a1 (D) (p = 0.003) negatively correlate
with apoptosis score, e.g. the less transcript, the more apoptotic
cells. In contrast, expression levels of down-regulated genes such as
Lyz 2 (B) (p < 0.001) and Pafah2 (E) (p = 0.005) postitively correlate
with apoptosis score. Samples from vitamin B6-treated rats (bare
circles) are arranged separately from samples of animals treated with
saline (solid circles).
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up-regulation of ETB receptor gene as a result of vitamin
B6 treatment.
Another important receptor also belonging to the GPCR
superfamily is the neuromedin B receptor (NMBR, ID
438637, Figure 4A). NMBR is localized in brain micro-
vascular endothelial cells that form the blood–brain bar-
rier. It is coupled to the phospholipase C transducing
system controlling the K+ efflux out of the brain [29]. A
down-regulation of NMBR in vitamin B6-treated rats may
be indicative for blood–brain barrier disruption induced
by BM.
The pro-inflammatory mediator IL-1 consists of 4 mo-
lecular species (IL-1α, IL-1β, IL-1γ and IL-1δ) that exert
similar biological activity through IL-1 receptor (IL-1R)
type I. In vivo studies showed that IL-1R−/− mice, lacking
an intact IL-1 signal, are more susceptible to develop
pneumococcal meningitis, and that the disease is associ-
ated with higher mortality in IL-1R−/− mice compared to
wild-type animals. These results suggest a protective role
of locally produced IL-1 in the first-line defense against
pathogens during pneumococcal meningitis [30]. How-
ever, in the present study, IL-1R type I (ID 381937,
Figure 4A) was down-regulated, indicating that upon
vitamin B6 treatment the host inflammatory reaction
is down-modulated.
Highly raised concentrations of CXC-chemokines (e.g.
IL-8) that attract neutrophils, and of CC-chemokines
(e.g. monocyte chemoattractant protein MCP-1, macro-
phage inflammatory proteins MIP-1α and MIP-1β) that
attract monocytes and lymphocytes, were observed in
the CSF during BM [31,32]. Chemokine receptors are
also GPCRs. In this study, CCR2 (ID 2818300), the re-
ceptor of MCP-1, and CCR5 (ID 382626), the receptor
of MIP-1α and MIP-1β, are down-regulated (Figure 4A).
Both receptors are expressed on glial and neuronal cells
in the adult brain as well as on neural progenitor cells
isolated from the subventricular zone where neurogen-
esis occurs. The localization of chemokine receptors in
these regions suggests an involvement of CCR2 and
CCR5 in the regulation of adult neural progenitor cells
in physiological or pathological conditions [33]. Other
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chemokine receptor associated with neuro-inflammatory
diseases such as multiple sclerosis and experimental auto-
immune encephalomyelitis [34]. However, the down-
regulation of CCR2 and CCR5 following vitamin B6
treatment may result in a reduced production of neuro-
inflammatory mediators by glial or neuronal cells. Further-
more, recruitment of monocytes and lymphocytes to the
CSF may also be reduced. Finally, it could also influence
the neurogenetic processes observed in the hippocampal
dentate gyrus (see below).
Following inflammation, microglial cells become acti-
vated and produce inflammatory mediators causing
brain damage in a variety of neurodegenerative dis-
orders. Since inflammation may exacerbate brain
damage, the control and reduction of brain inflamma-
tion is pathophysiologically important. IL-13 is an
anti-inflammatory cytokine which minimizes the pro-
duction of inflammatory mediators from activated
microglia (e.g. TNFα and MIP-1α) [35]. Moreover, ex-
perimental studies showed that exogenous IL-13 se-
lectively induces apoptotic death of activated microglia
[36]. Another study demonstrated that neurons and
microglia cooperatively down-regulate brain inflam-
mation by inducing endogenous IL-13 expression in
microglia, resulting in microglial death and elevation
of neuronal survival [35]. Suggesting a reduced inflam-
matory reaction as assessed by a down-regulation of pro-
inflammatory cytokines (IL-1R type I) and chemokines
(CCR2 and CCR5) in vitamin B6-treated rats, the require-
ment for anti-inflammatory cytokines such as IL-13 is
reduced. This suggestion is consistent with the down-
modulation of the IL-13 receptor alpha 1 (ID 432716,
Figure 4A) gene upon vitamin B6 treatment.
In summary, vitamin B6 down-modulates the inflam-
matory response as evidenced by reduced RNA levels
encoding for pro-inflammatory cytokines and chemo-
kines, and by transcriptional indication for diminished
activation of microglia. Because the brain damage ob-
served in BM, including hippocampal apoptosis, is
mainly due to the host inflammatory reaction [37], a
down-modulated immune reaction may decisively con-
tribute to diminished hippocampal apoptosis observed
in vitamin B6-treated rats. Evidence for strong anti-
inflammatory effects of vitamin B6 in patients with sys-
temic inflammatory symptoms has also been provided
by others [38-40].
Circadian rhythm
The circadian rhythm is generated by a set of interacting
genes and proteins (see Additional file 3: Figure S2). For
example in mammals, the protein products of the clock
and Bmal1 genes act together to induce the expression
of other clock genes including period (PER) [41]. Theup-regulation of period homolog transcripts (PER1, ID
395923, and PER2, ID 392428) in vitamin B6- compared
to placebo-treated rats suggests an involvement of the
circadian rhythm in the regulation of apoptotic pro-
cesses (Figure 4B).
Recent studies demonstrated a circadian periodicity of
the TRP metabolism via the KYN pathway [42]. How-
ever, TRP metabolism in the brain mainly occurs via 2
different pathways, the methoxyindole and the KYN
pathway. In experimental models as well as in humans,
melatonin, the main metabolite of the methoxyindole
pathway, acts as neuroprotective agent. It inhibits the
NMDA receptor and thus, protects the neurons from
excitotoxic damage. The same effect is mediated by
KYNA, a neuroprotective metabolite of the KYN path-
way. The inhibition of the NMDA receptor activity par-
tially depends on the reduction of the NO synthase
activity, therefore decreasing the amount of NO pro-
duced as a result of NMDA activation. Melatonin also
follows a circadian rhythmic pattern, mainly determined
by the pineal gland that increases the production of
melatonin upon physiological stimuli such as darkness.
Activation of either the methoxyindole or the KYN path-
way reaches an equilibrium in normal conditions by an
increase in the TRP degradation via the KYN pathway
during the day and via the methoxyindole pathway dur-
ing the night [43]. This equilibrium is lost under condi-
tions of stress including febrile and epileptic seizures
and probably also in other pathological situations [44].
BM displaying a stress situation could influence the
equilibrium between the methoxyindole and the KYN
pathway. Because vitamin B6 acts as a cofactor for 2 key
enzymes of the KYN pathway and also positively affects
the pineal production of melatonin [43], administration
of vitamin B6 could restore this equilibrium. Therefore,
melatonin as a immunomodulatory agent could play an
important role in neuroinflammation and subsequent
brain injury [45].
The elevation of cellular NAD+ levels through the
vitamin B6 induced activation of the KYN pathway ob-
served in this study, may also have an influence on fac-
tors involved in the circadian rhythm described above.
NAD+ has been shown to act as a central circadian
regulator. Concerning the role of NAD+ in cellular en-
ergy stores, a molecular coupling between the circadian
rhythm and energy metabolism has been proposed
[46-48]. Moreover, a link between disruption of circadian
rhythm and hippocampal learning and memory has been
reported in rats using the water maze task. Chronic
stress, sleep deprivation and decreases in melatonin se-
cretion are some of the many side effects of circadian
disruption. By its anti-oxidant and neuroprotective role
in the brain, melatonin deprivation may contribute
to brain damage in individuals suffering from chronic
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Alzheimer’s disease, melatonin treatment may reduce
the deposition of β-amyloid and protects against oxida-
tive stress. A possible speculation is that with decreasing
levels of melatonin, individuals suffering from chronic
circadian disruption become more vulnerable to brain
damage associated with learning and memory impair-
ment [49]. Another study showed that the clock gene
could have an important role on spatial learning in mice,
as assessed by water maze [50]. Furthermore, experi-
mental mouse models suggest that cell cycle and apop-
totic processes may be regulated by circadian clock
genes in bone marrow [41].
Neuronal signaling
Neurogenesis, the continuous production of new neu-
rons from a population of dividing neural progenitor
cells, occurs in the hippocampal dentate gyrus. It is
influenced by pathological situations such as ischemia or
inflammation. BM may affect the production of neuronal
survival factors such as brain-derived neurotrophic factor
(BDNF, ID 382982, Figure 4C) gene, thereby promoting
the survival of neuronal cells and thus, having an impact
on neurogenetic processes [51].
Recent studies demonstrated that the expression of
BNDF and its receptor TrkB is increased in mature neu-
rons during the acute phase of pneumococcal meningitis
[1]. BDNF protein co-localizes with cells expressing
TrkB in the hippocampal CA3/4 region and the hilus ad-
jacent to the subgranular zone of the dentate gyrus
where the proliferation of progenitor cells is increased.
These findings indicate an involvement of endogenous
BDNF and TrkB signaling in neurogenesis after BM [23].
However, the persistence of neurological sequelae in up
to 50% of survivors from BM [1,3] suggests that en-
dogenous mechanisms responsible for neuroregeneration
are inefficient.
Since treatment with exogenous BDNF results in the
reduction of various forms of cell death in experimental
pneumococcal meningitis [52], one can speculate that
the up-regulated expression level of BDNF in vitamin
B6-treated animals plays an important role in dimini-
shing hippocampal apoptosis.
BDNF induces the expression of many genes in hippo-
campal cells in culture, including activity regulated cyto-
skeletal-associated protein (ARC, ID 382171, Figure 4C)
gene. ARC itself is involved in memory consolidation
and long-term potentiation [53]. Because injury to the
hippocampal dentate gyrus is associated with learning
and memory deficits [5], the up-regulation of ARC RNA
in our study provides further evidence for a role of
BDNF in the reduction of hippocampal apoptosis.
Another gene involved in neuronal signaling processes
is early growth response 2 (EGR2, ID 438557, Figure 4C).EGR2 is an important mediator of the growth-suppressive
signal of phosphatase and tensin homolog (PTEN) and
plays a key role in the PTEN-induced apoptotic path-
way. It alters the permeability of mitochondrial mem-
branes, resulting in the release of cytochrome c which
in turn activates caspase-3, -8 and −9. As an alternative
route, EGR2 may directly induce the expression of
pro-apoptotic factors of the Bcl-2 family [54]. In the
present study, EGR2 is up-regulated by vitamin B6
treatment. This result is not consistent with a reduction
of apoptotic cell death by vitamin B6. This discrepancy
between an induction of apoptosis by EGR2 and an up-
regulation of EGR2 under circumstances that have been
proven to diminish apoptosis may be due to different
experimental conditions. In both studies, the molecular
mechanisms of the apoptotic pathway were analyzed by
microarrays, but we used an in vivo model system of
BM, whereas cancer-derived cells served as in vitro cul-
ture system for the study performed by Unoki and
Nakamura [54]. Furthermore, posttranslational mecha-
nisms such as phosphorylation, important for the
biological activity of PTEN, are not considered in
microarray experiments.
Members of the nuclear receptor subfamily 4 group A
(NR4A) are classified as early response genes expressed
in a wide variety of metabolically demanding and energy
dependent tissues such as the brain. They are induced
by a broad range of signals, including stress, growth fac-
tors, inflammatory cytokines, hormones, calcium, neuro-
transmitters and physical stimuli. Consistent with the
pleiotropic physiological stimuli inducing the NR4A
members, these receptors have been implicated in cell
cycle regulation, apoptosis, neurological disease, inflam-
mation, carcinogenesis and atherogenesis [55]. Since BM
is an inflammatory disease associated with brain damage
due to hippocampal apoptosis and often leads to neu-
rological deficits, the NR4A subfamily may play an es-
sential role in this disease. In the present study, both
member 1 and 2 of the NR4A family (NR4A1, ID
382110, and NR4A2, ID 438446) are up-regulated, sug-
gesting an involvement in apoptotic processes (Figure 4C).
Recent studies showed that the role of the Nr4A members
in cancer is largely defined by the implication of the sub-
family in the regulation of apoptosis [55]. Furthermore,
experimental studies with macrophages demonstrated an
involvement of NR4A1 in modulating apoptosis in the in-
flammatory response. Recent work also suggested that in
certain cell lines NR4A1 translocates to the mitochondria
to release cytochrome c [56].
Apoptosis/cell death
Platelet activating factor (PAF) is an extremely potent
activator of inflammatory cells owing to the expression
of its receptor by numerous cells of the innate immune
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or intracellular PAF acetylhydrolases is predicted to in-
hibit inflammatory signaling. Indeed, expression of
plasma PAF acetylhydrolase is increased by stimulation
with inflammatory agonists such as LPS, and decreased
by anti-inflammatory drugs [57]. Given the possible anti-
inflammatory effect of vitamin B6 as suggested by reduced
levels of pro-inflammatory mediators (e.g. cytokines and
chemokines) and diminished activation of inflammatory
cells (e.g. microglia), vitamin B6 may down-regulate
the expression of PAF hydrolase. This hypothesis was
tested by the vitamin B6 induced attenuation of PAF
acetylhydrolase 2 (PAFAH2, ID 549642, Figure 4D)
levels in our study.
PAF induces apoptosis independent of its receptor, but
the mechanism underlying this ability is not fully under-
stood [57]. However, PAFAH2 hydrolyzes not only PAF
but also short-chain phospholipids [58]. These subs-
trates are pro-apoptotic, pointing to an essential role of
PAFAH2 as anti-apoptotic agent [57]. Recent studies
reported that a transfection of the plasma PAFAH2 gene
reduces glutamate-induced apoptosis in cultured rat cor-
tical neurons. Moreover, studies using a mouse model of
focal cerebral ischemia showed that PAFAH2 exerts
strong neuroprotective effects against ischemic injury in
the CNS by protecting neurons against oxidative stress
[58]. In this context, it seems that down-regulated
PAFAH2 does not contribute to the processes leading
to the reduced hippocampal apoptosis in vitamin B6-
treated rats.
Beside the role of matrix metalloproteinases (MMPs)
in blood–brain barrier disruption and extravasation of
inflammatory cells into the CNS [3,59], recent studies
suggested an involvement of MMPs in glial and neuronal
cell death. Furthermore, an excessive increase of MMP-9
(ID 382260, Figure 4D) in BM has been identified as a
risk factor for the development of neurological sequelae
[59]. Therefore, the down-regulation of MMP-9 upon
vitamin B6 treatment indicates a long-term effect of
vitamin B6 in terms of reduced learning and memory
impairments.
MMPs are also increased by antimicrobial peptides.
Antimicrobial peptides are effector molecules of the in-
nate immune system with antibiotic function. Aside
from their antibiotic functions, they may be involved in
immune responses and inflammatory disease. For ex-
ample, they may amplify inflammation by activation of
cytokine and chemokine expression in immune cells
[60]. Lysozyme (Lyz) is an antimicrobial protein belong-
ing to the defensin family of host-defense proteins which
are distributed widely in biological fluids and tissues. Ex-
perimental studies with transgenic mice showed that Lyz
raises the levels of antioxidant reserves that are required
to manage non-pathological amounts of reactive oxygenspecies. These antioxidant properties are partly mediated
via negative regulation of stress response genes (e.g.
c-Jun) and also involve the blockade of cellular apoptosis
in vitro [61]. However, Brandenburg et al. reported that
there is no increase of Lyz in the CSF and serum sam-
ples from patients with meningitis [60]. In the present
study, we found a down-regulation of Lyz 2 (ID 378051,
Figure 4D) in vitamin B6-treated rats when compared to
saline-treated animals. This down-regulation could be a
further indication of a reduced inflammation and in
this context, would explain the reduced levels of pro-
inflammatory cytokines and chemokines.
Recent studies showed that adjuvant BDNF protects
the brain from caspase 3-dependent hippocampal apop-
tosis in experimental BM [13]. In the present study,
up-regulated endogenous BDNF is also involved in
apoptotic processes as indicated by the apoptotic cell
death cluster (Figure 4D). This result provides further
evidence for a crucial role of BDNF in reducing hippo-
campal apoptosis upon vitamin B6 treatment.
But how does vitamin B6 induce BDNF expression?
Several studies showed that BDNF expression in neur-
onal cells is induced by activation of calcium channels
and recruitment of calcium-sensitive transcription fac-
tors [62]. The excitatory amino acid glutamate which is
increased in interstitial brain fluid in BM [63] induces a
calcium influx by binding to the NMDA receptor and
thus, may stimulate the production of BDNF [64]. On
the contrary, KYNA, the neuroprotective intermediate of
the KYN pathway, is an antagonist of the NMDA recep-
tor and therefore, inhibits calcium influx. Moreover,
in vitro studies using rat cerebral cortex nerve terminals
showed that vitamin B6 inhibits glutamate release
through the suppression of calcium influx [65].
However, other studies reported that high levels of
IL-1β decrease BDNF mRNA expression in the rat
hippocampus [66]. Thus, the increased amount of BDNF
transcripts in vitamin B6-treated rats may result from
decreased levels of IL-1β. This suggestion is also sup-
ported by the down-regulation of the IL-1R type I gene
as discussed previously.
A related phenomenon could be observed in the
brains of rats administered an antibiotic plus dexa-
methasone. Given the up-regulation of BDNF RNA and
protein in this study, Li et al. hypothesize that the adju-
vant therapy with dexamethasone might have a benefi-
cial effect on BM via up-regulation of neuroprotective
BDNF. In addition, this study demonstrated a dose-
dependent down-regulation of BDNF RNA and protein
in rats treated with antibiotics alone. A possible reason
for this finding is the lysis of bacteria caused by the anti-
biotic treatment, resulting in the release of bacterial
components that stimulate the expression of pro-
inflammatory mediators such as IL-1β [66].
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Pre-treatment with vitamin B6 in BM exerts neuropro-
tective effects in terms of reduced apoptosis in the hip-
pocampal dentate gyrus of infant rats. Although the
processes required for this effect need more investiga-
tion, preservation of cellular energy stores, reduction of
the inflammatory response and up-regulation of BDNF
expression may, at least partially, explain the neuro-
protective properties of vitamin B6 in models of pneu-
mococcal meningitis.
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Additional file 3: Figure S2. Circadian rhythm. Pathway analysis of
significantly regulated genes according to KEGG database. The genes are
stained according to their regulation level: Green marked genes are
up-regulated, red marked genes are down-regulated and light green
stained genes are on control level.
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